Could a pill keep endometrial cancer at bay? new study tests rucaparib
NCT ID NCT03617679
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether the drug rucaparib can help keep metastatic or recurrent endometrial cancer from growing. 79 women who had already received chemotherapy took either rucaparib or a placebo pill twice daily. The goal was to see if rucaparib could delay cancer progression and improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rucaparib (a PARP inhibitor drug taken as a pill)
- What this could lead to
- If successful, rucaparib could offer a new maintenance option to delay cancer progression in people with advanced endometrial cancer.
- What could go wrong
- This is a Phase 2 trial with only 79 participants, so results may not be definitive. Rucaparib can cause side effects like fatigue, nausea, and low blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Colorado Hospital
Aurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug tackle Hard-to-Treat gynecologic cancers?
- Can Immune-Boosting drugs tame recurrent endometrial cancer?
- Could a targeted drug shrink recurrent endometrial tumors?
- New drug combo shows promise for Tough-to-Treat uterine cancer
- New combo shows promise for Tough-to-Treat uterine cancer
- New drug combo targets Hard-to-Treat cancers in early trial